medigraphic.com
ISSN 0188-9796 (Impreso)

2007, Número 3

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2007; 15 (3)


Polipéptido insulinotrópico dependiente de glucosa y péptido semejante al glucagón tipo 1: acciones fisiológicas e implicaciones en la diabetes tipo 2 y la obesidad

Romero ZA

Idioma: Español
Referencias bibliográficas: 63
Paginas: 156-164
Archivo PDF: 129.28 Kb.


RESUMEN

El péptido semejante al glucagón tipo 1 (GLP-1) y el polipéptido insulinotrópico dependiente de glucosa (GIP) son las principales hormonas responsables del efecto incretínico. Por consecuencia, el efecto fisiológico más relevante de ambas hormonas es la regulación de la homeostasis de la glucosa posterior a la ingesta de alimentos a través de la estimulación de la secreción insulina y diversas acciones extrapancreáticas. En modelos experimentales se han observado proliferación de las células betas, efectos cardioprotectores regulación de las grasas en el adipocito y promoción de la formación ósea. Los sujetos con diabetes tipo 2 presentan una leve disminución de la secreción de GLP-1 y un defecto de la actividad insulinotrópica de GIP. GIP participa en la génesis de la obesidad y la resistencia a la insulina inducida por dietas con alto contenido de grasas en ciertos tipos de ratones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Elrick H, Stimmler L, Hlad Jr CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-1082.

  2. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-1962.

  3. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969; 123: 261-226.

  4. Dupre J, Ross Sa, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-828.

  5. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like-peptide-2 stimulates insulin release from isolated rat pancreatic islets, Diabetologia 1985; 28: 704-707.

  6. Fehmann HC, Goke B. Cell and molecular biology of the incretin hormones glucagon-like petide 1 and glucose dependent insulin releasing polypeptide. Endocrin Rev 1995; 16: 390-410.

  7. Mortensen K, Petersen LL, Orskov C . Colocalization of GLP-1 and GIP in human and porcine intestine. Ann NY Acad Sci 2000; 921: 469-472.

  8. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117-124.

  9. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122: 531-544.

  10. Elliott RM, Morgan LMJA, Tredger S, Deacon J. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-166.

  11. Rask T, Olsson S, Soderberg O, Johnson J. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001; 24: 1640-1645.

  12. Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop, Endocrinology 1993; 133: 233-240.

  13. Larsen PH, Holls JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul pept 2005; 128: 97-107.

  14. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706-2713.

  15. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-3581.

  16. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-613.

  17. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.

  18. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995: 44: 1126-113.

  19. Ruiz-Grande C, Alarcon C, Alcantara A, Lopez NJM, Villanueva-Penacarrillo ML. Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 1993: 25. 612-616.

  20. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003: 55: 167-194.

  21. Wei Y, Mojsov SS. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences, FEBS Lett 1995: 358; 219-224.

  22. Holst JJ , Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E2006.

  23. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430-441.

  24. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004; (11-12): 747-754.

  25. Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 2006; 55Suppl 2: S86-91.

  26. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-796.

  27. Buteau J, Hui H, Bertelotto C. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004; 47: 806-815.

  28. Hollz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361: 362-365.

  29. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counter regulatory hormone responses, cognitive functions and insulin secretion during hyperinsulinemic stepped hypoglycaemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab, 2002; 87: 1239-1246.

  30. Samols E, Bonner-Weir S, Weir GC. Intra-islet insulin–glucagon–somatostatin relationships. Clin Endocrinol Metab 1986: 15: 33-58.

  31. Wettergren A, Schjoldager B, Mortensen PE et al. Effect of GLP-1 on gastric motility and gastric and pancreatic secretion in man. Digestion 1993; 54: 384-385.

  32. Imeryuz N, Yegen B, Bozkurt A et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273: G920-G927.

  33. Flint A, Raben A, Astrup A et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.

  34. Naslund E, Barkeling B, King N et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304-311.

  35. Gutzwiller JP, Drewe J, Goke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-R1544.

  36. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997; 138: 4445-4455.

  37. Gros R, You X, Baggio LL et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144: 2242-2252.

  38. Yu M, Moreno C, Hoagland KM. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-1135.

  39. 39 Gutzwiller JP, Tschopp S, Bock A et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men, J Clin Endocrinol Metab 2004; 89: 3055-3061.

  40. Perry T, Lahiri DK, Chen D et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002; 300: 958-966.

  41. 41 During MJ, Cao L, Zuzga DS et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-1179.

  42. Yip RGC, Wolfe MM. GIP biology and fat metabolism. Life Sciences 2000; 66: 91-103.

  43. Getty-Kaushik L, Song DH, Boylan MO, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity 2006: 14; 1124-1131.

  44. Katsushi Tsukiyama, Yuichiro Yamada, Chizumi Yamad et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 2006; 20: 1644-1651.

  45. Xie D, Zhong Q, Ding KH, Cheng H, Williams S, Correa D, Bollag WB, Bollag RJ, Insogna K, Troiano N, Coady C, Hamrick M, Isales CM. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 2007; 40: 1352-1360.

  46. ÃÜrskov C. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415-423.

  47. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.

  48. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.

  49. Meier JJ. Insulin secretion. In Endocrinology. Edited by DeGroot LJ, Jameson JL. Elsevier Saunders; 2005: 961-973.

  50. Nauck MA , Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.

  51. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2719-2725.

  52. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.

  53. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.

  54. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45: 1111-1119.

  55. Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE, Nauck MA. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric in hibitory polypeptide (GIP) in patients with type 2 diabetes and healthy control subjects. Diabetes 2004; 53(suppl 3): S220-S224.

  56. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004-1011.

  57. Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, McIntosh CH, Pederson RA. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J 2003; 17: 91-93.

  58. Nauck MA, El-Ouaghlidi A, Gabrys B et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004; 122: 209-217.

  59. Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA. Similar insulin secretory response to a GIP bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 2003; 52: 1579-1585.

  60. Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide (GIP) in women with a history of gestational diabetes. Diabetologia 2005; 48:872-1881.

  61. Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003; 88: 4897-4903.

  62. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.

  63. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J. Clin. Invest 2007; 117: 143-152.




2020     |     www.medigraphic.com